EHR to EDC: New software solution ‘ingests’ output data as solution to interoperability

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/shansekala)
(Image: iStock/shansekala)
Crucial Data Solutions, Inc. and its strategic partner Zircon Technologies have teamed up to release a “first-of-its-kind” software solution developed to accelerate the clinical trials process.

Crucial Data Solutions and Zircon Technologies joined together with the common goal to lower the cost and duration of clinical research​,” said Carley Allison, director of marketing, Crucial Data Solutions

When asked how AccelEDC is different from similar solutions, Allison told us to the company’s knowledge, the technology is the first of its kind and “there are currently no solutions with similar capabilities​.”

Allison explained AccelEDC addresses the electronic health record (EHR) to electronic data capture (EDC) interoperability problem from a different angle: “instead of attempting to integrate with an EHR system, this platform simply ingests EHR output data, such as doctor's notes and PDF documents through the utilization of a lightweight API​.” 

According to the companies, the technology was developed in response to the challenge of source data verification.

The platform enables clinical research coordinators (CRCs) to export PDF files containing data, text notes, and adverse events from an EHR system. The data is anonymized with the Zircon Technologies’ AccelEDC desktop app before it is uploaded to the Crucial Data Solutions’ EDC system, Clinical Studio.

The solution also adheres to 21 CFR Part 11​ and HIPAA regulations.

The California-based contract research organization (CRO), Oncotherapeutics, is implementing AccelEDC at one of its sites in a pilot study in early 2018.

Related news

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers